

**ADVENTA BERHAD**  
(Company No : 200301016113 (618533-M))  
(Incorporated in Malaysia)  
**FIRST QUARTER REPORT ENDED 31 MARCH 2022**  
**UNAUDITED NOTES TO FINANCIAL STATEMENTS**

**PART A - EXPLANATORY NOTES PURSUANT TO MFRS 134**

**1. BASIS OF PREPARATION**

The interim financial report is unaudited and has been prepared in accordance with Malaysia Financial Reporting Standard ("MFRS") 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2021. The explanatory notes attached to the interim financial statements explain events and transactions that are significant to the understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2021.

The audited financial statements of the Group for the year ended 31 December 2021 were prepared in accordance with Malaysian Financial Reporting Standards ("MFRS"). The significant accounting policies and method of computations adopted in the preparation of the financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 December 2021.

**2. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS**

The preceding audited financial statements for the year ended 31 December 2021 were no subject to any qualification.

**3. UNUSUAL ITEMS DUE TO THEIR NATURE, SIZE OR INCIDENCE**

There were no other unusual items affecting assets, liabilities, equity, net income, and cash flows during the current quarter under review.

**4. CHANGES IN ESTIMATES**

There were no changes in estimates that have had a material effect on the current quarter results.

**5. DEBTS AND EQUITY SECURITIES**

There were no issuances, cancellations, repurchases, resale, and repayments of debt and equity securities during the current quarter under review.

**6. DIVIDENDS PAID**

There was no dividend paid during the current quarter under review.

**ADVENTA BERHAD**  
 (Company No : 200301016113 (618533-M))  
 (Incorporated in Malaysia)  
**FIRST QUARTER REPORT ENDED 31 MARCH 2022**

**UNAUDITED NOTES TO FINANCIAL STATEMENTS**

**7. TRADE AND OTHER RECEIVABLES**

	<b>As at 31-Mar-22 RM ('000)</b>	<b>As at 31-Dec-21 RM ('000)</b>
<b>Trade Receivables</b>		
Third parties	29,625	37,965
Allowance for impairment loss	(3,790)	(3,790)
	25,835	34,175
<b>Other Receivables</b>		
Third and Related parties	7,813	12,499
Allowance for impairment loss	-	-
	7,813	12,499
Deposits and Prepayments	2,529	2,510
	36,177	49,184

**a) Trade Receivables**

The Group's normal trade credit term ranges from 30 to 90 days (2021: 30 to 90 days). Other credit terms are assessed and approved on a case-by-case basis. They are recognized at their original invoice amounts which represent their fair value on initial recognition.

The Group recognizes loss allowances for expected credit losses (ECLs) on trade receivables measured at amortised cost. The Group applies the simplified approach to provide ECLs for all trade receivables as permitted by MFRS 9.

The following table provides information about the exposure to credit risk and ECLs for trade receivables:

	<b>As at 31-Mar-22 RM ('000)</b>	<b>As at 31-Dec-21 RM ('000)</b>
Not past due	12,562	16,887
Past due:		
- Less than 30 days	3,791	12,996
- 31 to 60 days	639	3,747
- 61 to 90 days	3,725	775
- More than 90 days	8,908	3,560
	29,625	37,965
Less: Loss allowance		
- Collectively impaired	(180)	(180)
- Individually impaired	(3,610)	(3,610)
Trade Receivable net	25,835	34,175

**ADVENTA BERHAD**  
 (Company No : 200301016113 (618533-M))  
 (Incorporated in Malaysia)  
**FIRST QUARTER REPORT ENDED 31 MARCH 2022**

**UNAUDITED NOTES TO FINANCIAL STATEMENTS**

Credit impaired

Trade receivables that are individually determined to be impaired at the reporting date relate to debtors that are in significant financial difficulties and have defaulted payments. These receivables are not secured by any collateral or credit enhancements.

**8. SEGMENTAL INFORMATION**

**Healthcare:** The business involves the supply of healthcare and related products, services to hospitals, healthcare centers and pharmacies. This includes the renal dialysis business which is for home and center-based treatments, serving both the domestic and export markets. This renal dialysis business was disposed of on 3 May 2021.

The Group's segmental revenue and profit/(loss) before tax (PBT/LBT) for the current quarter are as follow:

<u>Revenue</u>	<b>Individual Quarter Ended</b>		<b>Cumulative Quarter Ended</b>	
	<b>31-Mar-22</b>	<b>31-Mar-21</b>	<b>31-Mar-22</b>	<b>31-Mar-21</b>
<u>Segment</u>	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>RM ('000)</b>
Healthcare	18,295	12,985	18,295	12,985
Corporate	240	409	240	409
Elimination	(240)	(438)	(240)	(438)
<b>Total</b>	<b>18,295</b>	<b>12,956</b>	<b>18,295</b>	<b>12,956</b>

  

<u>PBT/(LBT) result</u>				
<u>Segment</u>	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>RM ('000)</b>
Healthcare	939	(1,171)	939	(1,171)
Corporate	(29)	(120)	(29)	(120)
Elimination	-	-	-	-
<b>Total</b>	<b>910</b>	<b>(1,291)</b>	<b>910</b>	<b>(1,291)</b>

**9. VALUATIONS OF PROPERTY, PLANT AND EQUIPMENT**

The valuations of property, plant and equipment have been brought forward, without amendment from the previous annual financial statements of the Group.

**ADVENTA BERHAD**  
**(Company No : 200301016113 (618533-M))**  
**(Incorporated in Malaysia)**  
**FIRST QUARTER REPORT ENDED 31 MARCH 2022**

**UNAUDITED NOTES TO FINANCIAL STATEMENTS**

**10. SIGNIFICANT EVENTS**

There are no material events subsequent to the end of the reporting period under review that have not been reflected in the quarterly financial statements.

**11. CHANGES IN COMPOSITION OF THE GROUP**

There were no changes in the composition of the Group during the financial period ended 31 March 2022.

**12. CONTINGENT LIABILITIES AND CONTINGENT ASSETS**

There were no contingent liabilities or contingent assets for the Group for the current quarter under review.

**13. CAPITAL COMMITMENTS**

There were no material capital commitments at the financial period ended 31 March 2022.

**ADVENTA BERHAD**  
 (Company No : 200301016113 (618533-M))  
 (Incorporated in Malaysia)  
**FIRST QUARTER REPORT ENDED 31 MARCH 2022**

**UNAUDITED NOTES TO FINANCIAL STATEMENTS**

***PART B – ADDITIONAL INFORMATION AS REQUIRED BY APPENDIX 9B OF BURSA MALAYSIA LISTING REQUIREMENTS***

**14. PERFORMANCE REVIEW**

	<b>Individual Quarter Ended 1Q 2022</b>	<b>Individual Quarter Ended 1Q 2021</b>	<b>Changes</b>	<b>Changes</b>
	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>%</b>
Revenue	18,295	12,956	5,339	41%
Profit before tax / (Loss before tax )	910	(1,291)	2,201	170%

Sales revenue improved by 41% over FY 2022 first quarter, reflecting the recovery of the healthcare sector.

Profit before tax is RM910 thousand compared to the previous quarter's loss of RM1.2 million, a turnaround driven by the divestment of a loss making subsidiary and improved operations in current segments.

**15. COMPARISON WITH PRECEDING QUARTER'S RESULTS**

	<b>Reporting Quarter 1Q 2022</b>	<b>Previous Quarter 4Q 2021</b>	<b>Changes</b>	<b>Changes</b>
	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>%</b>
Revenue	18,295	22,642	(4,347)	-19%
Profit Before Tax (PBT)	910	2,701	(1,791)	-66%

This quarter recorded a drop in revenue of RM4.3 million compared to the previous quarter and a lower profit before tax by RM1.79 million. In the current quarter, there is a change in hospitals' protocols and health policies as the country gradually embraces endemicity and we saw a shift in demand and usage of selected hospital products especially the personal protective equipment ("PPE") range. The closure of Mega Vaccination Centers ("PPV") has resulted in slower offtake of vaccination related supplies.

**16. COMMENTARY ON CURRENT YEAR PROSPECTS**

With the reopening of borders and recovering from Covid-19, there may be short-term headwinds as demand for certain Covid-19 related products taper off. However, we see increasing volumes and occupancy to pre-pandemic levels in the hospitals as the situation normalizes. Products for surgical and operating rooms is back in demand now. The Company has sustained the profitability trend this quarter and expects to continue for the current year unless current inflationary pressures and logistics challenges continue unabated.

**ADVENTA BERHAD**  
 (Company No : 200301016113 (618533-M))  
 (Incorporated in Malaysia)  
**FIRST QUARTER REPORT ENDED 31 MARCH 2022**

**UNAUDITED NOTES TO FINANCIAL STATEMENTS**

**17. PROFIT FORECAST**

No profit forecast was announced hence there was no comparison between actual results and forecast.

**18. TAXATION**

The effective tax rate is higher than the statutory rate due to certain expenses being disallowed for tax purposes.

	<b>Individual Quarter Ended</b>		<b>Cumulative Quarter Ended</b>	
	<b>31-Mar-22</b>	<b>31-Mar-21</b>	<b>31-Mar-22</b>	<b>31-Mar-21</b>
	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>RM ('000)</b>	<b>RM ('000)</b>
Income tax credit/(expense)	(372)	-	(372)	-
Deferred tax assets/(liabilities)	-	-	-	-
<b>Total</b>	<b>(372)</b>	<b>-</b>	<b>(372)</b>	<b>-</b>

**19. SALE OF UNQUOTED INVESTMENTS AND PROPERTIES**

There was no sale of unquoted investments and properties during the current quarter under review.

**20. MARKETABLE SECURITIES**

There was no purchase or disposal of marketable securities during the current quarter under review.

**21. CORPORATE PROPOSALS**

(i) Proposed Private Placement and/or Proposed Shares Subscription

The Company had on 8 Dec 2021 made an application to Bursa Malaysia for a Proposed Share Issuance of up to 20% of the total number of issued shares (“Proposed Share Issuance”) and entered into a Subscription Agreement with Macquarie Bank Limited (“Macquarie”) granting them the right to subscribe for up to 15 million of new Adventa Shares.

On 10 December 2021, the Company had obtained approval from Bursa Malaysia for the listing of and quotation for 30,557,154 new Adventa Shares (“Placement Shares”) representing 20% of the Company’s total number of issued shares.

**ADVENTA BERHAD**  
**(Company No : 200301016113 (618533-M))**  
**(Incorporated in Malaysia)**  
**FIRST QUARTER REPORT ENDED 31 MARCH 2022**

**UNAUDITED NOTES TO FINANCIAL STATEMENTS**

On 31 March 2022, the Subscription Agreement with Macquarie had expired and the Company has not placed out any placement shares to any third-party investor.

On 26 May 2022, the Company had made application to Bursa Malaysia for the extension of time (“EOT”) of the Proposed Share Issuance for another 6 months from 9 June 2022 and allow all the Placement Shares to be issued to third-party investor(s) in view of the expiry of the Subscription Agreement with Macquarie.

The Company will sought shareholders’s approval for 20% General Mandate (“20% General Mandate”) at the forthcoming Annual General Meeting which is schedule to be held on 23 June 2022.

(ii) Proposed Employee Share Scheme (“Proposed ESS”)

On 28 March 2022, the Company proposed to undertake the establishment of an employee share scheme, which comprises the proposed employee share option scheme (“Proposed ESOS”) and the proposed share grant plan (“Proposed SGP”), of up to 15% of the total number of issued shares in the Company (excluding treasury shares of Adventa, if any) at any point in time during the duration of the employee share scheme, for eligible employees and Directors of the Company and its subsidiaries (“Eligible Persons”), which are not dormant, who fulfill the eligibility criteria as set out in the by-laws of the employee share scheme. (“ Proposed ESS”)

On 22 April 2022, Bursa Malaysia Securities Berhad had granted the approval for the implementation of the Proposed ESS and the scheme is currently pending shareholders’ approval at the forthcoming Annual General Meeting (“AGM”) which is schedule to be held on 23 June 2022.

Save for the above, there was no other corporate proposal announced as at the date of this interim report but pending completion.

**22. BANK BORROWINGS AND DEBT SECURITIES**

The total bank borrowings of the Group as of financial year ended 31 March 2022 as below.

	<b>As at 31-Mar-22 RM ('000)</b>	<b>As at 31-Mar-21 RM ('000)</b>
<b>Current (Secured):</b>		
Trade loan	1,207	-
Term Loan	-	1,000
Total Bank Borrowings	1,207	1,000

**ADVENTA BERHAD**  
 (Company No : 200301016113 (618533-M))  
 (Incorporated in Malaysia)  
**FIRST QUARTER REPORT ENDED 31 MARCH 2022**

**UNAUDITED NOTES TO FINANCIAL STATEMENTS**

**23. CHANGES IN MATERIAL LITIGATION**

The Board confirms that the Adventa Group is not engaged in any material litigation, claims or arbitration, either as plaintiff or defendant. The Board has no knowledge of any proceedings pending against Adventa Group or any facts likely to give rise to any proceeding which may have a material impact on the business or the financial position of Adventa Group.

**24. EARNINGS PER SHARE**

The basic and diluted earnings per share for the reporting period are computed as follows:

**a. Basic**

	<b>Individual Quarter Ended</b>		<b>Cumulative Quarter Ended</b>	
	<b>31-Mar-22</b>	<b>31-Mar-21</b>	<b>31-Mar-22</b>	<b>31-Mar-21</b>
Profit attributable to ordinary equity holders of the parent (RM '000)	700	(1,122)	700	(1,122)
Weighted average number of ordinary shares in issue (Unit '000)	152,786	152,786	152,786	152,786
Basic earnings per share (sen)	0.46	(0.73)	0.46	(0.73)

**b. Diluted**

There were no diluted earnings per share.

**25. (LOSS) / PROFIT BEFORE TAX**

(Loss) / profit before tax is stated after charging/(crediting):

	<b>Individual Quarter Ended</b>		<b>Cumulative Quarter Ended</b>	
	<b>31-Mar-22</b>	<b>31-Mar-21</b>	<b>31-Mar-22</b>	<b>31-Mar-21</b>
	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>
Other income	49	94	49	94
Interest income	69	9	69	9
Net foreign exchange loss/(gain)	(108)	(95)	(108)	(95)
Interest expenses	(334)	(353)	(334)	(353)



**ADVENTA BERHAD**  
 (Company No : 200301016113 (618533-M))  
 (Incorporated in Malaysia)  
**FIRST QUARTER REPORT ENDED 31 MARCH 2022**

**UNAUDITED NOTES TO FINANCIAL STATEMENTS**

**26. REALISED AND UNREALISED PROFITS/(LOSSES)**

The breakdown of the retained profits of the Group as at reporting date into realised and unrealised profits/(losses) is as follows:

	<b>As at 31-Mar-2022</b>	<b>As at 31-Mar-2021</b>
<b>Group's total (Accumulated losses)/Retained profits:</b>	<b>RM'000</b>	<b>RM'000</b>
Realised	16,659	(32,949)
Unrealised	(3,931)	(13,870)
<b>Total Realised and unrealised</b>	<b>12,728</b>	<b>(46,819)</b>
Less: Consol adjustments	1,429	43,170
(Accumulated losses) / Retained profits	<b>11,299</b>	<b>(3,649)</b>

**27. AUTHORISED FOR ISSUE**

The interim financial statements were authorized for issue by the Board of Directors in accordance with a resolution of the directors on 27<sup>th</sup> May 2022.

**By Order of the Board**  
**Adventa Berhad**  
**CHUA SIEW CHUAN**  
 Company Secretary MAICSA 0777689